In PLOS this week: profile of a yeast mycoparasite, biology of complex diseases, and more.
The researchers plan to analyze clinical records and genetic data from whole-exome sequencing for more than 3,000 patients using DNAnexus' Apollo platform.
Clinical trials investigating whether epigenetic treatment can restore susceptibility to other treatments are underway in colorectal, lung, and breast cancers.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
With the three-year grants, the institutions will continue an initiative that is developing tools and technologies for genome biology research.
The test is designed to analyze a panel of 112 genes to help in the diagnosis of thyroid nodules with indeterminate fine-needle aspiration cytology.
The groups will conduct a study evaluating the benefits of targeted next-generation sequencing in the diagnosis and care of infants with genetic disorders.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
Scientific American reports that drugs being pursued to treat small fraction of Parkinson's disease patients with a certain gene mutation could also help a larger portion of patients.
The genome center will be equipped with five Illumina NovaSeq instruments and will support clinical research at the Immune Therapy and Transplantation Center.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.